Menu
Log in


Log in


About PGRN

Who We Are

A new PGRN, PGRN IV, established July 1, 2015, represents a continuation of these research activities, however in a new model. This new model invites participation of all investigators with an interest in pharmacogenomics research to be part of the new network.

Currently, the newly formed PGRN consists of three large center grant projects, two enabling resources for pharmacogenomics, a knowledgebase, PharmGKB, and a PGRN Hub, established to coordinate activities of the new PGRN in order to catalyze research in pharmacogenomics and precision medicine.

Our Objective

The mission of the Pharmacogenomics Global Research Network (PGRN) is to catalyze and lead research in precision medicine for the discovery and translation of genomic variation influencing therapeutic and adverse drug effects.

Member Benefits

  • Reduced registration fees for PGRN meetings and workshops, including member receptions and poster sessions at annual ASHG (and ASCPT) meeting.
  • Participation in member-wide quarterly calls/webinars and monthly Research in Progress Seminars
  • Membership on PGRN program committees for meetings and workshops
  • Network with colleagues and establish collaborations
  • Leadership opportunities for members (e.g., serve on PGRN committees, board, and as leaders)
  • Awards for trainees
  • Access to PGRN web pages highlighting pharmacogenomics tools and resources, events and other useful information for PGx research, education and clinical practice
  • Mentorship opportunities

Resources

Pharmacogenomics Knowledgebase (PharmGKB)

The PharmGKB is a resource that encompasses clinical information including dosing guidelines and drug labels, potentially clinically actionable gene-drug associations and genotype-phenotype relationships.

Clinical Pharmacogenomics Implementation (CPIC)

CPIC’s goal is to address some of the barriers to implementation of pharmacogenetic tests into clinical practice.

Our History

The Pharmacogenomics Research Network, PGRN I–III was funded from 2000 through 2015 by multiple Institutes and Centers of the NIH. The network catalyzed pharmacogenomics discoveries both nationally and internationally through the conduct of collaborative research focused on the discovery and translation of the genetic determinants of drug response, in order to enable safer and more effective drug therapies.


Powered by Wild Apricot Membership Software